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Abstract 
Termination of protein biosynthesis is an essential step of gene expression, during which a 
complete functional protein is released from the ribosome. Premature or inefficient termination 
results in truncated, non-functional or toxic proteins that may cause disease. Indeed, more than 
10% of human genetic diseases are caused by nonsense mutations leading to premature 
termination. Efficient and sensitive approaches are required to study eukaryotic termination 
mechanisms and to identify potential therapeutics that modulate termination. Canonical 
radioactivity-based termination assays are complex, report on a short peptide release, and are 
incompatible with high-throughput screening. Here we describe a robust and simple in vitro 
assay to study the kinetics of full-protein release. The assay monitors luminescence upon 
release of nanoluciferase from a mammalian pre-termination complex. The assay can be used 
to record time-progress curves of protein release in a high-throughput format, making it optimal 
for studying release kinetics and for high-throughput screening for small molecules that 
modulate the efficiency of termination. 
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Introduction 
Translation termination occurs when the ribosome recognizes a stop codon in the A site. In 
eukaryotes, stop codons UAA, UGA and UAG are decoded by release factor eRF1 aided by 
GTPase eRF3 (Hellen 2018). Termination defines the lengths of all cellular proteins and is 
therefore a critical step of gene expression. Indeed, many genetic diseases are caused by 
nonsense mutations, which result in premature release of truncated proteins that can be non-
functional or toxic (Mort et al. 2008). Termination is regulated by sequence and structure of the 
mRNA downstream the stop codon (Brar 2016; Cridge et al. 2018), and by interactions between 
release factors and other proteins (Ivanov et al. 2016; Kashima et al. 2006; Mikhailova et al. 
2017). For example, poly-A-binding protein (PABP) and the position of a stop codon relative to 
the poly-A tail affect the efficiency of termination, and are associated with the severity of 
nonsense-mutation diseases (Mort et al. 2008; Wu et al. 2019). Mechanistic understanding of 
termination, including accuracy, efficiency, and dependence on mRNA sequence and protein 
factors requires a robust quantitative termination assay. Furthermore, assays amenable to high-
throughput drug screening are needed to identify drugs that modulate or prevent termination at 
premature nonsense codons. 
In vitro biochemical assays have extensively informed our understanding of bacterial translation 
termination. For example, kinetic assays have been used to characterize the efficiency of 
release factors on different codons (Freistroffer et al. 2000; Hoernes et al. 2018), how release 
factor mutations affect termination (Nakamura and Ito 1998), and how antibiotics inhibit bacterial 
termination (Youngman et al. 2007; Svidritskiy et al. 2013). They have also revealed that the 
efficiency of termination depends on the length of the peptidyl moiety attached to tRNA, 
suggesting that longer peptides are more efficient than single-aminoacyl-tRNA (Zavialov et al. 
2001; Alkalaeva et al. 2006). Furthermore, full-protein folding at the end of termination might 
affect the efficiency of release (Goldman et al. 2015). Nevertheless, release of full-length protein 
has not been extensively studied using canonical in vitro assays in bacterial systems. 
Eukaryotic in vitro termination assays are even less accessible. A tour-de-force mammalian in 
vitro termination assay requires more than a dozen translation factors, which must be purified 
and assembled into a pre-termination complex (Eyler and Green 2011; Alkalaeva et al. 2006; 
Ng et al. 2018). These assays usually use an mRNA coding for a short peptide (4-6 amino 
acids) to monitor release of a radioactively labeled peptide (Alkalaeva et al. 2006).Thus, the 
kinetics of full-length protein release from eukaryotic ribosomes remains unaddressed.  
Radioactive labeling is a major limitation of termination assays, as it makes kinetic 
measurements cumbersome and renders the assays unsuitable for high-throughput small-
molecule screening.  
We have developed a robust assay to measure the release of full-length protein from 
mammalian ribosomes. The assay measures release of a 19-kDa nanoluciferase, whose C-
terminal tail must fold onto the rest of the protein to form an active catalytic domain (Fig. 1A and 
(Dixon et al. 2016)). Nanoluciferase has several advantages over the larger firefly luciferase, 
which is commonly used as a reporter. Compared to firefly luciferase, nanoluciferase 
luminescence is at least an order of magnitude greater, more stable over time, and less 
dependent on temperature and pH  (England et al. 2016). Finally, nanoluciferase requires a 
luciferin-like substrate (furimazine) but does not require ATP, which can chelate Mg2+ and may 
interfere with translation assays and high-throughput screens for small-molecule modulators of 
translation (Auld and Inglese 2004).  
Our assay can be used to record time-progress curves of protein release by release factors and 
puromycin, an aminoacyl-tRNA mimic that stimulates protein release by covalently attaching to 
its C-terminus. Release factor eRF1 induces efficient release, which can be inhibited by mutant 
release factor or small-molecule inhibitor G418. Finally, we demonstrate that the sensitive 
readout in a microplate luminescence reader can be used to efficiently monitor the inhibition of 
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release, making the assay amenable to high-throughput screens to identify or optimize 
therapeutics.  
Results and Discussion 
Our assay is based on the premise that the nascent tRNA-bound nanoluciferase is inactive 
because its C-terminal region—essential for luminescence (Dixon et al. 2016)—is occluded by 
the ribosomal polypeptide tunnel (Fig 1A-B; (Jha and Komar 2011)). We hypothesized that the 
release of nanoluciferase results in the appearance of luminescence upon fast (millisecond 
range) folding of nanoluciferase into an active state (Dixon et al. 2016). Indeed, in rabbit 
reticulocyte lysates, nanoluciferase mRNA with a stop codon produced luminescence, but a 
nanoluciferase mRNA without a stop codon (to prevent protein release) produced no 
luminescence (Fig. 1C). This result echoes a study of firefly luciferase, showing that the 
corresponding mRNA without a stop codon produces no luminescence (Kolb et al. 1994).  
Adding puromycin to the stalled non-stop translation complexes stimulates luminescence, 
indicating the release of nanoluciferase (Fig. 1C).  
 
Figure 1. The schematic of the nanoluciferase pre-termination complex. (A) Crystal structure of 
nanoluciferase. C-terminal aminoacids (129-169; red) likely occupy the polypeptide tunnel of the 
ribosome in the pre-termination complex. (B) mRNA constructs used to monitor nanoluciferase release. 
(C) Progress of nanoluciferase mRNA translation in rabbit reticulocyte lysate: stop-codon containing 
mRNA is shown in green brown and non-stop mRNA translation followed by addition of puromycin is 
yellow (relative luminescence units (RLU) are on the y axis). 
We next optimized the purification of pre-termination complexes on an in vitro transcribed full-
length nanoluciferase mRNA with a UAA stop codon, β-globin 5′- and 3′-UTRs, and a 30-nt poly-
A tail (Fig. 1B). Translation of mRNA was initiated in the commercial nuclease-treated rabbit 
reticulocyte lysates using a standard set of reagents (Fig. 2A; Methods). To stall translation on 
the stop codon without releasing the protein, we added catalytically inactive eRF1AGQ (catalytic 
GGQ motif mutated to AGQ) (Frolova et al. 1999; Brown et al. 2015). The stalled 80S was 
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purified by sucrose gradient fractionation (Fig. 2A; Methods), which removes eRF1AGQ (Shao et 
al. 2016) and results in a pre-termination 80S complex with nanoluciferase-tRNA in the P site 
and a vacant A site containing a stop codon (Fig. 1A). 
We tested whether adding purified recombinant eRF1 or puromycin to purified pre-termination 
complexes would stimulate release of nanoluciferase and luminescence. The reactions were 
carried out in 20 μl volumes using a microplate luminescence reader. Indeed, both eRF1 and 
puromycin stimulated release of nanoluciferase. 0.6 μM human eRF1 released nanoluciferase 
with an apparent rate constant of ~0.4 min-1 (obtained by single-exponential fitting; Fig. 2B), 
similar to rates observed for human eRF1 on pre-termination complexes assembled in vitro 
(Alkalaeva et al. 2006). Puromycin released nanoluciferase faster than eRF1, but the 
luminescence signal over time remained low (Fig. 2B), suggesting the puromycin adduct may 
interfere with nanoluciferase activity. Importantly, the pre-termination complexes do not 
spontaneously release nanoluciferase (buffer control, Fig. 2B), in contrast to the complexes with 
short peptides showing substantial background release that is only few-fold slower than eRF1-
induced release (Alkalaeva et al. 2006). High stability of the nanoluciferase pre-termination 
complex is an excellent property to derive accurate kinetic parameters.  
 
Figure 2. Preparation of the 80S pre-termination complex and nanoluciferase release kinetics. (A) 
Purification of the 80S pre-termination nanoluciferase complex stalled on the stop codon in rabbit 
reticulocyte lysate, using sucrose gradient fractionation. (B) Time progress curves showing luminescence 
(in relative luminescence units, RLU) of the 80S pre-termination nanoluciferase complex upon treatment 
with recombinant human eRF1 (blue), puromycin (yellow) or buffer (negative control, brown). (C) Time 
progress curves showing luminescence (in relative luminescence units, RLU) of the 80S pre-termination 
nanoluciferase complex incubated with recombinant yeast eRF1y  and treated by yeast eRF3y (green) or 
buffer (negative control, blue). Exponential fits are shown by black lines. 20 μl reactions were performed 
in a microplate reader.  
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Translation termination in eukaryotes is accelerated by the GTPase protein eRF3 (Zhouravleva 
et al. 1995; Alkalaeva et al. 2006; Eyler et al. 2013). We therefore asked if eRF3 synergizes with 
eRF1 in our nanoluciferase release assay. We used yeast eRF1y and eRF3y, which were shown 
to function in heterologous eukaryotic systems (Ng et al. 2018). We adjusted eRF1y 
concentration to 0.01 μM, so that nanoluciferase release was negligible (Fig. 2C). Addition of 
0.05 μM eRF3y•GTP resulted in fast increase in luminescence, in keeping with efficient protein 
release by eRF1•eRF3•GTP termination complex (Fig. 2C).  
 
Figure 3. Competitive inhibition of eRF1-induced release of nanoluciferase from purified 80S pre-
termination complexes. (A) Luminescence in the presence of wild-type eRF1 or equimolar amounts of 
wild-type eRF1 and catalytically inactive eRF1AGQ (0.6 μM). (B) Luminescence in the presence of wild-
type eRF1 and different concentrations of G418. (C) Dependence of catalytic rates (kobs) for eRF1-
mediated release of nanoluciferase on G418 concentration. IC50 was determined by hyperbola fitting (red) 
of kobs values obtained at different concentrations of G418 and 0.6 μM human eRF1. Error bars represent 
standard deviation of the mean. (n=3). (D) Alignment of G418-bound 80S decoding center (red; 
(Prokhorova et al. 2017)) with that of eRF1-bound 80S termination complex carrying a UAA stop codon 
(gray; (Brown et al. 2015)) shows steric clash of G418 with A1824.  
 
We next tested if our in vitro release assay is suitable for characterizing termination inhibitors. 
As an example of a competitive inhibitor, we used the catalytically inactive eRF1AGQ. As 
expected, release was substantially slower in the presence of equimolar amounts of human 
eRF1 and eRF1AGQ than eRF1 alone (Fig. 3A; 0.6 μM).  
We then asked whether G418, an aminoglycoside that induces stop-codon readthrough 
(Dabrowski et al. 2018; Wangen and Green 2020), inhibits nanoluciferase release. Stop-codon 
readthrough by G418 and other aminoglycosides could be primarily due to: (a) misreading of the 
stop codon by a near-cognate tRNA (Prokhorova et al. 2017); (b) inhibition of eRF1; or (c) a 
combination of (a) and (b). On bacterial ribosomes, aminoglycosides both induce miscoding 
(Davies et al. 1965) and inhibit translation termination (Youngman et al. 2007). But bacterial 
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release factors RF1 and RF2, and their interactions with the stop codons (Laurberg et al. 2008; 
Weixlbaumer et al. 2008; Korostelev et al. 2008, 2010) substantially differ from those in 
eukaryotic eRF1-bound termination complexes (Brown et al. 2015; Matheisl et al. 2015). It 
therefore remains unclear whether G418 efficiently inhibits eukaryotic termination.  
We found that G418 inhibited eukaryotic translation termination with an IC50 of 64 ± 20 μM (Figs. 
3B and 3C), similar to that for  bacterial termination inhibition by paromomycin (~35 μM; 
(Youngman et al. 2007)). Inhibition of termination is consistent with the structural mechanism of 
G418 binding to the decoding center of the eukaryotic ribosome (Prokhorova et al. 2017) and 
inducing the bulged conformations of nucleotides A1824-A1825 (18S rRNA nucleotides of H. 
sapiens ribosome; corresponding to A1492 and A1493 of E. coli ribosome; Fig. 3D). In this 
conformation, the adenosines would clash with the U-turn conformation of the stop codon. 
Furthermore, G418 would clash with A1824 docking within helix 44 upon eRF1 binding (Fig. 
3D). These data suggest that modest inhibition of eRF1 may synergize with the ability of G418 
to induce decoding of the stop codon by a near-stop tRNA, explaining the readthrough.  
Conclusions 
We have developed a robust and versatile translation termination assay. The luminescence-
based assay is straightforward, more efficient than assays that measure release of radioactive 
peptides, and suitable for studies of full-protein release on ribosomes from almost any 
organism. Our assay can be used to study the regulation of translation termination, including 
how the context of a stop codon—i.e., sequences or structures surrounding the stop codon—
affects termination. Indeed, nanoluciferase can report on release from mRNAs with and without 
a 3' UTR (Figs. 1, 2), indicating that varying stop codon identities and downstream sequences 
can be tested. While our manuscript was under review, firefly luciferase was reported to capture 
the effects of different 3' UTR sequences and other factors on termination in cell-free translation 
(Lashkevich et al. 2020), highlighting that distinct luciferase reporters can be harnessed for 
quantitative termination analyses. Furthermore, sequences upstream of the stop codon can be 
introduced in our method to study the proposed effects of the ORF on termination (Pierson et al. 
2016). The last ~13 amino acid residues of nanoluciferase are essential for activity, and 
nanoluciferase retains luminescence upon C-terminal extension (Dixon et al. 2016). Since the 
polypeptide tunnel can occlude ~40 amino acids (Jha and Komar 2011), the nanoluciferase C-
terminus can be extended by up to 25 varying amino acid sequences to study the effects of  the 
mRNA preceding the stop codon.  Lastly, the ability to measure termination in a microplate 
reader makes the assay suitable for high-throughput screens to identify termination modulators 
and potential therapeutics for genetic diseases caused by nonsense mutations.  
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Materials and Methods 
Plasmids and mRNA constructs 
DNA plasmids encoding nanoluciferase constructs were designed as follows. Nanoluciferase 
sequence from pNL1.1[Nluc] Vector (Promega) was inserted into pUC57(Kan) plasmid 
(Genscript), flanked by β-globin 5'- and 3'-UTRs. Templates for in vitro transcription were 
generated using PCR. For FULL mRNA, a pair of primers annealing to the globin UTRs was 
used: the forward primer (tttttTAATACGACTCACTATAGacacttgcttttgacacaactgtg) containing a 
T7-promoter and the reverse primer with a 30-nt poly-T-stretch 
(ttttttttttttttttttttttttttttttGCAATGAAAATAAATTTCCTTTATTAGCC). For the NO-STOP, mRNA a 
reverse primer annealing to the 3'-end of nanoluciferase coding sequence was used 
(CGCCAGAATGCGTTCGCAC). In vitro transcription with recombinant T7 RNA polymerase 
was done as described (Alkalaeva et al. 2006); transcription products were precipitated with 
2.5M LiCl, washed with 80%-ethanol and dissolved in deionized water. Concentrations of 
mRNAs were determined using Nanodrop 2000 (Thermo Fischer).  
Purification of human eRF1, eRF1AGQ and yeast eRF1 and eRF3 
His-tagged recombinant proteins were expressed in E.coli  and purifiied as described (Frolova 
et al. 1998, 2000) for human eRF1, eRF1AGQ , and in (Eyler et al. 2013) for yeast eRF1 and 
eRF3.  
In vitro translation reaction in RRL 
Reaction mixture containing 50% of nuclease-treated rabbit reticulocyte lysate (RRL) (Promega) 
was supplemented with 30 mM Hepes-KOH (pH=7.5), 50 mM KOAc, 1.0 mM Mg(OAc)2, 0.2 mM 
ATP and GTP, 0.04 mM of 20 aminoacids (Promega), and 2mM DTT. Nanoluciferase substrate 
furimazine (Promega) was added to the mixture at 1%. 10 μl aliquots of the mixture were placed 
in 384-well plate (Corning Low Volume White Round Bottom) and incubated at 30°C for 5 min in 
microplate reader (Tecan INFINITE M1000 PRO). Translation reactions were started by addition 
of mRNA (final concentration 10ng/μl) and luminescence signal was recorded. At 900 sec, 1 ul 
of water (control) or puromycin solution in water were added (100 uM final concentration in the 
reaction). The resulting data were processed in Microsoft Excel.   
Preparation of the pre-termination complex and rabbit reticulocyte lysate 
Purification of pre-termination complexes was done from 1 ml translation mixtures described 
above. To stall translation progress at the stop-codon, reaction mixture was preincubated with 1 
μM eRF1AGQ at 30°C for 10 min followed by the addition of FULL mRNA to the final 
concentration of 8 μg/ml and incubation at 300 C for 25 min. Using this mRNA concentration 
resulted in predominant formation of monosomic 80S complexes (see representative sucrose 
gradient profile in Fig. 2A). Then, KoAC concentration was adjusted to 300 mM and the mixture 
was layered on 10-35% linear gradient of sucrose in buffer A (50 mM Hepes-KOH, pH=7.5, 7.5 
mM Mg(OAc)2, 300 mM KOAc, 2mM DTT), prepared using Gradient Profiler system (Biocomp). 
The gradients were centrifuged in SW-41 Ti (Beckman Coulter) rotor at 40000g for 2.5 hours 
(Beckman Coulter Optima TLX). Gradient Profiler was used to collect fractions corresponding to 
the monosomic 80S-mRNA ribosomes. The sample was concentrated using Amicon® Ultra-15 
Centrifugal Filter Units (Millipore Sigma), yielding ~50 nM ribosome (One A260 unit = 20 nM 
80S ribosomes, using Nanodrop 2000 (Thermo Fischer). Ribosome solution was aliquoted, 
flash-frozen in liquid nitrogen and stored at -800C. After 5 months of storage, the complexes 
retained ~70% of the initial signal level (compare Figure 3A and 3B).   
 
Kinetic reactions with purified nanoluciferase-ribosome complexes 
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80S solution was diluted to ~15 nM with buffer B (50 mM Hepes-KOH, pH=7.5, 0.25 mM 
spermidine, 2mM DTT), supplemented with 1% nanoluciferase substrate (Promega), aliquoted 
(20 μl) and placed in a 384-well plate. The samples were incubated at 30°C for 5 min in the 
absence/presence of 0.6 μM eRF1AGQ or 10-1000 μM G418 (Gold Biotechnology) to test 
inhibition by the eRF1 mutant or G418. Release reaction was started by the addition of 0.6 μM 
human eRF1, or 100 μM puromycin, or 0.01 μM yeast eRF1y followed by the addition of 0.05 
μM yeast eRF3y with 0.2 mM GTP, and luminescence was recorded. Buffer C (20mM Tris-HCI, 
pH=7.5, 100mM KCI, 6 mM 2-Mercaptoethanol, 10% glycerol) or water were used as negative 
control. The data were plotted and fitted in GraphPad Prism 8 using single-exponential fits to 
obtain kobs values, and in Gnuplot using hyperbola fitting to obtain IC50.   
Structural analysis and visualization 
Structural analysis and visualization were done in PyMol (Schrödinger) using PDB 5IBO for 
nanoluciferase (Lovell, S., to be published), PDB 5NDG for G418-bound yeast ribosome 
(Prokhorova et al. 2017) and PDB 3JAG for eRF1-bound mammalian ribosome(Brown et al. 
2015). Yeast and mammalian ribosomes were aligned by 18S rRNA. All figures were assembled 





 Cold Spring Harbor Laboratory Press on September 30, 2020 - Published by rnajournal.cshlp.orgDownloaded from 
References 
 
Alkalaeva EZ, Pisarev A V., Frolova LY, Kisselev LL, Pestova T V. 2006. In Vitro Reconstitution 
of Eukaryotic Translation Reveals Cooperativity between Release Factors eRF1 and eRF3. 
Cell 125: 1125–1136. 
Auld DS, Inglese J. 2004. Interferences with Luciferase Reporter Enzymes. 
http://www.ncbi.nlm.nih.gov/pubmed/27478246. 
Brar GA. 2016. Beyond the Triplet Code: Context Cues Transform Translation. Cell 167: 1681–
1692. 
Brown A, Shao S, Murray J, Hegde RS, Ramakrishnan V. 2015. Structural basis for stop codon 
recognition in eukaryotes. Nature 524: 493–6.  
Cridge AG, Crowe-Mcauliffe C, Mathew SF, Tate WP. 2018. Eukaryotic translational termination 
efficiency is influenced by the 3′ nucleotides within the ribosomal mRNA channel. Nucleic 
Acids Res 46: 1927–1944. 
Dabrowski M, Bukowy-Bieryllo Z, Zietkiewicz E. 2018. Advances in therapeutic use of a drug-
stimulated translational readthrough of premature termination codons. Mol Med 24. 
Davies J, Gorini L, Davis BD. 1965. Misreading of RNA codewords induced by aminoglycoside 
antibiotics. Mol Pharmacol 1: 93–106.  
Dixon AS, Schwinn MK, Hall MP, Zimmerman K, Otto P, Lubben TH, Butler BL, Binkowski BF, 
MacHleidt T, Kirkland TA, et al. 2016. NanoLuc Complementation Reporter Optimized for 
Accurate Measurement of Protein Interactions in Cells. ACS Chem Biol 11: 400–408. 
England CG, Ehlerding EB, Cai W. 2016. NanoLuc: A Small Luciferase Is Brightening Up the 
Field of Bioluminescence. Bioconjug Chem 27: 1175–1187. 
Eyler DE, Green R. 2011. Distinct response of yeast ribosomes to a miscoding event during 
translation. Rna 17: 925–932. 
Eyler DE, Wehner KA, Green R. 2013. Eukaryotic release factor 3 is required for multiple 
turnovers of peptide release catalysis by eukaryotic release factor 1. J Biol Chem 288: 
29530–29538. 
Freistroffer D V., Kwiatkowski M, Buckingham RH, Ehrenberg M. 2000. The accuracy of codon 
recognition by polypeptide release factors. Proc Natl Acad Sci U S A 97: 2046–2051. 
Frolova LY, Merkulova TI, Kisselev LL. 2000. Translation termination in eukaryotes: Polypeptide 
release factor eRF1 is composed of functionally and structurally distinct domains. Rna 6: 
381–390. 
Frolova LY, Simonsen JL, Merkulova TI, Litvinov DY, Martensen PM, Rechinsky VO, Camonis 
JH, Kisselev LL, Justesen J. 1998. Functional expression of eukaryotic polypeptide chain 
release factors 1 and 3 by means of baculovirus/insect cells and complex formation 
between the factors. Eur J Biochem 256: 36–44. 
Frolova LY, Tsivkovskii RY, Sivolobova GF, Oparina NY, Serpinsky OI, Blinov VM, Tatkov SI, 
Kisselev LL. 1999. Mutations in the highly conserved GGQ motif of class 1 polypeptide 
release factors abolish ability of human eRF1 to trigger peptidyl-tRNA hydrolysis. RNA 5: 
1014–1020. 
Goldman DH, Kaiser CM, Milin A, Righini M, Tinoco I, Bustamante C. 2015. Mechanical force 
releases nascent chain-mediated ribosome arrest in vitro and in vivo. Science (80- ) 348: 
457–460. 
Hellen CUT. 2018. Translation termination and ribosome recycling in eukaryotes. Cold Spring 
 Cold Spring Harbor Laboratory Press on September 30, 2020 - Published by rnajournal.cshlp.orgDownloaded from 
Harb Perspect Biol. 
Hoernes TP, Clementi N, Juen MA, Shi X, Faserl K, Willi J, Gasser C, Kreutz C, Joseph S, 
Lindner H, et al. 2018. Atomic mutagenesis of stop codon nucleotides reveals the chemical 
prerequisites for release factor-mediated peptide release. Proc Natl Acad Sci U S A 115: 
E382–E389. 
Ivanov A, Mikhailova T, Eliseev B, Yeramala L, Sokolova E, Susorov D, Shuvalov A, Schaffitzel 
C, Alkalaeva E. 2016. PABP enhances release factor recruitment and stop codon 
recognition during translation termination. Nucleic Acids Res 44: 7766–7776.  
Jha S, Komar AA. 2011. Birth, life and death of nascent polypeptide chains. Biotechnol J 6: 
623–640. 
Kashima I, Yamashita A, Izumi N, Kataoka N, Morishita R, Hoshino S, Ohno M, Dreyfuss G, 
Ohno S. 2006. Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon 
junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay. 
Genes Dev 20: 355–367. 
Kolb VA, Makeyev EV, Spirin AS. 1994. Folding of firefly luciferase during translation in a cell-
free system. EMBO J 13: 3631–3637. 
Korostelev A, Asahara H, Lancaster L, Laurberg M, Hirschi A, Zhu J, Trakhanov S, Scott WG, 
Noller HF. 2008. Crystal structure of a translation termination complex formed with release 
factor RF2. Proc Natl Acad Sci U S A 105: 19684–19689. 
Korostelev A, Zhu J, Asahara H, Noller HF. 2010. Recognition of the amber UAG stop codon by 
release factor RF1. EMBO J 29: 2577–2585.  
Lashkevich KA, Shlyk VI, Kushchenko AS, Gladyshev VN, Alkalaeva EZ, Dmitriev SE. 2020. 
Ctels: A cell‐free system for the analysis of translation termination rate. Biomolecules. 
Laurberg M, Asahara H, Korostelev A, Zhu J, Trakhanov S, Noller HF. 2008. Structural basis for 
translation termination on the 70S ribosome. Nature 454: 852–7.  
Matheisl S, Berninghausen O, Becker T, Beckmann R. 2015. Structure of a human translation 
termination complex. Nucleic Acids Res 43: 8615–8626. 
Mikhailova T, Shuvalova E, Ivanov A, Susorov D, Shuvalov A, Kolosov PM, Alkalaeva E. 2017. 
RNA helicase DDX19 stabilizes ribosomal elongation and termination complexes. Nucleic 
Acids Res 45: 1307–1318. 
Mort M, Ivanov D, Cooper DN, Chuzhanova NA. 2008. A meta-analysis of nonsense mutations 
causing human genetic disease. Hum Mutat 29: 1037–1047. 
Nakamura Y, Ito K. 1998. How protein reads the stop codon and terminates translation. Genes 
to Cells 3: 265–278. 
Ng MY, Zhang H, Weil A, Singh V, Jamiolkowski R, Baradaran-Heravi A, Roberge M, Jacobson 
A, Friesen W, Welch E, et al. 2018. New in Vitro Assay Measuring Direct Interaction of 
Nonsense Suppressors with the Eukaryotic Protein Synthesis Machinery. ACS Med Chem 
Lett 9: 1285–1291. 
Pierson WE, Hoffer ED, Keedy HE, Simms CL, Dunham CM, Zaher HS. 2016. Uniformity of 
Peptide Release Is Maintained by Methylation of Release Factors. Cell Rep. 
Prokhorova I, Altman RB, Djumagulov M, Shrestha JP, Urzhumtsev A, Ferguson A, Chang 
CWT, Yusupov M, Blanchard SC, Yusupova G, et al. 2017. Aminoglycoside interactions 
and impacts on the eukaryotic ribosome. Proc Natl Acad Sci U S A 114: E10899–E10908. 
Shao S, Murray J, Brown A, Taunton J, Ramakrishnan V, Hegde RS. 2016. Decoding 
Mammalian Ribosome-mRNA States by Translational GTPase Complexes. Cell 167: 1229-
 Cold Spring Harbor Laboratory Press on September 30, 2020 - Published by rnajournal.cshlp.orgDownloaded from 
1240.e15. 
Svidritskiy E, Ling C, Ermolenko DN, Korostelev AA. 2013. Blasticidin S inhibits translation by 
trapping deformed tRNA on the ribosome. Proc Natl Acad Sci U S A 110: 12283–12288. 
Wangen JR, Green R. 2020. Stop codon context influences genome-wide stimulation of 
termination codon readthrough by aminoglycosides. Elife 9. 
Weixlbaumer A, Jin H, Neubauer C, Voorhees RM, Petry S, Kelley AC, Ramakrishnan V. 2008. 
Insights into Translational Termination from the Structure of RF2 Bound to the Ribosome. 
Science (80- ) 322: 953–956. 
Wu C, Roy B, He F, Jacobson A. 2019. Nonsense Suppression Position Effect Implicates 
Poly(A)-Binding Protein in the Regulation of Translation Termination. SSRN Electron J. 
Youngman EM, He SL, Nikstad LJ, Green R. 2007. Stop Codon Recognition by Release 
Factors Induces Structural Rearrangement of the Ribosomal Decoding Center that Is 
Productive for Peptide Release. Mol Cell 28: 533–543. 
Zavialov A V., Buckingham RH, Ehrenberg M. 2001. A posttermination ribosomal complex is the 
guanine nucleotide exchange factor for peptide release factor RF3. Cell 107: 115–124. 
Zhouravleva G, Frolova L, Le Goff X, Le Guellec R, Inge-Vechtomov S, Kisselev L, Philippe M. 
1995. Termination of translation in eukaryotes is governed by two interacting polypeptide 
chain release factors, eRF1 and eRF3. EMBO J 14: 4065–4072. 
 
 Cold Spring Harbor Laboratory Press on September 30, 2020 - Published by rnajournal.cshlp.orgDownloaded from 
 published online August 14, 2020RNA
  
Denis Susorov, Shawn Egri and Andrei A Korostelev
  
ribosomes









manuscript is likely to differ from the final, published version. 










(Attribution-NonCommercial 4.0 International), as described at 




 click here.top right corner of the article or 
Receive free email alerts when new articles cite this article - sign up in the box at the
 http://rnajournal.cshlp.org/subscriptions
 go to: RNATo subscribe to 
Published by Cold Spring Harbor Laboratory Press for the RNA Society
 Cold Spring Harbor Laboratory Press on September 30, 2020 - Published by rnajournal.cshlp.orgDownloaded from 
